Ondansetron - ADial Pharmaceuticals

Drug Profile

Ondansetron - ADial Pharmaceuticals

Alternative Names: AD-04

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ADial Pharmaceuticals
  • Class Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Small molecules; Smoking cessation therapies
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alcoholism
  • Phase I Obesity; Opioid abuse; Smoking withdrawal

Most Recent Events

  • 02 Aug 2017 ADial Pharmaceuticals plans phase II trials for Obesity, Drug abuse and Smoking withdrawal (ADial Pharmaceuticals pipeline, August 2017)
  • 02 Aug 2017 ADial Pharmaceuticals completes a phase IIb trial in Alcoholism before August 2017 (ADial Pharmaceuticals pipeline, August 2017)
  • 29 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top